147 related articles for article (PubMed ID: 31785335)
21. Regulation of autophagic cell death by glycogen synthase kinase-3β in adult hippocampal neural stem cells following insulin withdrawal.
Ha S; Ryu HY; Chung KM; Baek SH; Kim EK; Yu SW
Mol Brain; 2015 May; 8():30. PubMed ID: 25986948
[TBL] [Abstract][Full Text] [Related]
22. Serine 9 and tyrosine 216 phosphorylation of GSK-3β differentially regulates autophagy in acquired cadmium resistance.
Park CH; Lee BH; Ahn SG; Yoon JH; Oh SH
Toxicol Sci; 2013 Oct; 135(2):380-9. PubMed ID: 23897984
[TBL] [Abstract][Full Text] [Related]
23. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
[TBL] [Abstract][Full Text] [Related]
24. Inositol synthesis regulates the activation of GSK-3α in neuronal cells.
Ye C; Greenberg ML
J Neurochem; 2015 Apr; 133(2):273-83. PubMed ID: 25345501
[TBL] [Abstract][Full Text] [Related]
25. The primary defect in glycogen synthase activity is not based on increased glycogen synthase kinase-3alpha activity in diabetic myotubes.
Gaster M; Brusgaard K; Handberg A; Højlund K; Wojtaszewski JF; Beck-Nielsen H
Biochem Biophys Res Commun; 2004 Jul; 319(4):1235-40. PubMed ID: 15194499
[TBL] [Abstract][Full Text] [Related]
26. Fine-Tuning of the RIG-I-Like Receptor/Interferon Regulatory Factor 3-Dependent Antiviral Innate Immune Response by the Glycogen Synthase Kinase 3/β-Catenin Pathway.
Khan KA; Dô F; Marineau A; Doyon P; Clément JF; Woodgett JR; Doble BW; Servant MJ
Mol Cell Biol; 2015 Sep; 35(17):3029-43. PubMed ID: 26100021
[TBL] [Abstract][Full Text] [Related]
27. Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells.
Wang Q; Zhou Y; Evers BM
Neoplasia; 2006 Sep; 8(9):781-7. PubMed ID: 16984735
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of IGF-I and GSK in the spinal cord of Kii and Guamanian ALS patients.
Kihira T; Suzuki A; Kondo T; Wakayama I; Yoshida S; Hasegawa K; Garruto RM
Neuropathology; 2009 Oct; 29(5):548-58. PubMed ID: 19323791
[TBL] [Abstract][Full Text] [Related]
29. Oxazolo[5,4-f]quinoxaline-type selective inhibitors of glycogen synthase kinase-3α (GSK-3α): Development and impact on temozolomide treatment of glioblastoma cells.
Hasyeoui M; Lassagne F; Erb W; Nael M; Elokely KM; Chaikuad A; Knapp S; Jorda A; Vallés SL; Quissac E; Verreault M; Robert T; Bach S; Samarat A; Mongin F
Bioorg Chem; 2023 May; 134():106456. PubMed ID: 36913879
[TBL] [Abstract][Full Text] [Related]
30. The GSK-3 family as therapeutic target for myocardial diseases.
Lal H; Ahmad F; Woodgett J; Force T
Circ Res; 2015 Jan; 116(1):138-49. PubMed ID: 25552693
[TBL] [Abstract][Full Text] [Related]
31. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
[TBL] [Abstract][Full Text] [Related]
32. The neuron-specific isoform of glycogen synthase kinase-3beta is required for axon growth.
Castaño Z; Gordon-Weeks PR; Kypta RM
J Neurochem; 2010 Apr; 113(1):117-30. PubMed ID: 20067585
[TBL] [Abstract][Full Text] [Related]
33. Abnormalities in brain structure and behavior in GSK-3alpha mutant mice.
Kaidanovich-Beilin O; Lipina TV; Takao K; van Eede M; Hattori S; Laliberté C; Khan M; Okamoto K; Chambers JW; Fletcher PJ; MacAulay K; Doble BW; Henkelman M; Miyakawa T; Roder J; Woodgett JR
Mol Brain; 2009 Nov; 2():35. PubMed ID: 19925672
[TBL] [Abstract][Full Text] [Related]
34. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia.
Neumann T; Benajiba L; Göring S; Stegmaier K; Schmidt B
J Med Chem; 2015 Nov; 58(22):8907-19. PubMed ID: 26496242
[TBL] [Abstract][Full Text] [Related]
36. The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.
Banerji V; Frumm SM; Ross KN; Li LS; Schinzel AC; Hahn CK; Kakoza RM; Chow KT; Ross L; Alexe G; Tolliday N; Inguilizian H; Galinsky I; Stone RM; DeAngelo DJ; Roti G; Aster JC; Hahn WC; Kung AL; Stegmaier K
J Clin Invest; 2012 Mar; 122(3):935-47. PubMed ID: 22326953
[TBL] [Abstract][Full Text] [Related]
37. Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer.
Chandra P; Sachan N; Pal D
Curr Drug Targets; 2021; 22(13):1548-1554. PubMed ID: 33538668
[TBL] [Abstract][Full Text] [Related]
38. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.
Coghlan MP; Culbert AA; Cross DA; Corcoran SL; Yates JW; Pearce NJ; Rausch OL; Murphy GJ; Carter PS; Roxbee Cox L; Mills D; Brown MJ; Haigh D; Ward RW; Smith DG; Murray KJ; Reith AD; Holder JC
Chem Biol; 2000 Oct; 7(10):793-803. PubMed ID: 11033082
[TBL] [Abstract][Full Text] [Related]
39. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
Lo Monte F; Kramer T; Gu J; Brodrecht M; Pilakowski J; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
Eur J Med Chem; 2013 Mar; 61():26-40. PubMed ID: 22749643
[TBL] [Abstract][Full Text] [Related]
40. Roles of Glycogen Synthase Kinase-3 (GSK-3) in Cardiac Development and Heart Disease.
Takahashi-Yanaga F
J UOEH; 2018; 40(2):147-156. PubMed ID: 29925734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
